ERBB2 and breast carcinoma: In this study, we investigated the potential of 89Zr (half-life (t1/2) ~ 3.27 days) labeled trastuzumab (Herceptin®) as a surrogate tool to monitor biologic effects of dasatinib treatment in HER2-positive (HER2+) breast cancer.